Buy & Sell Prologis Inc (PLD) – Prologis Inc Price Today
Aura AI Summary
Key Stats
- $130.50BMarket Cap
- Real EstateSector
- -5.9%3M Drawdown
- $164.37BEnterprise Value
- 3.06%Dividend Yield
- 99 daysTypical Hold Time
Prologis Inc (PLD) is currently valued at a market capitalization of $130.50B, with an enterprise value of $164.37B. Over the past 52 weeks, Prologis Inc has traded between a low of $104.08 and a high of $148.74, highlighting its annual price range. Over the past three months, Prologis Inc has recorded a drawdown of -5.9%, reflecting recent price volatility. Prologis Inc offers a dividend yield of 3.06%, with the most recent dividend of $1.07 paid on 16 Jun 26. On average, investors hold Prologis Inc for approximately 99 days, indicating typical investor behavior on the platform.
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Most Recent News
Study shows 1 in 7 patients switch back to Humira after moving to biosimilars post-formulary changes
A new study analyzing nearly 68,000 US patients found that adoption of adalimumab biosimilars increased significantly after formulary changes, but over 16% of those who switched from Humira reverted back to the original drug. The research highlights ...

Biogen shareholders to receive $18.9M in proposed class action settlement for stock purchases in 2021
A proposed $18.9 million class action settlement has been approved by a U.S. District Court for investors who purchased Biogen Inc. common stock between June 8 and July 12, 2021. The settlement aims to resolve claims against Biogen and certain execut...

Caribou Biosciences CEO to speak at H.C. Wainwright Cell Therapy Conference June 30, 2026
Caribou Biosciences, a clinical-stage CRISPR biopharma company, announced that CEO Rachel Haurwitz will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. The event highlights Caribou's ...
